Cameco Sees Production Halted At Inkai Joint Venture
Cameco (TSX: CCO) is off to a rough start to 2025, with the company announcing this morning that production at its Inkai LLP joint venture with Kazatomprom has been halted as of January 1.
The production halt is in relation to the submission of documentation for uranium deposit development to authorities in Kazakhstan. The joint venture previously believed that it would receive an extension of the timeline to submit the required documentation, however this did not materialize due to a delayed submission to the Ministry of Energy.
Cameco further claims that as of a report dated December 26, no mention of the possibility for a production halt was provided. The company at this time has not indicated the severity of the production and financial impacts for 2025 and 2026, with Cameco currently in the process of seeking clarification.
WATCH: Cameco Q3 Earnings: A Mixed Bag
The Inkai joint venture is 40% owned by Cameco, with the remainder owned by Kazatomprom. In 2023 the operation produced 8.3 million pounds of U3O8 on a 100% basis, while Cameco’s share of estimated reserves totals 105.7 million pounds of U3O8.
Cameco last traded at $73.91 on the TSX.
Information for this story was found via the sources and the companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
